N-Desmethylclobazam is primarily used as an active metabolite of clobazam, contributing to the therapeutic effects of the parent drug. It is utilized in the management of epilepsy, particularly in the treatment of Lennox-Gastaut syndrome, a severe form of childhood epilepsy. The metabolite enhances the anticonvulsant activity by modulating GABAergic neurotransmission, which helps in reducing seizure frequency and severity. Additionally, it is sometimes monitored in clinical settings to assess patient adherence to clobazam therapy and to optimize dosing regimens for better seizure control. Its role in therapeutic drug monitoring ensures that patients receive effective and safe treatment, minimizing the risk of adverse effects.